Peng, Shansen Xie, Zhouzhou Jiang, Huiming Zhang, Guihao Chen, Nanhui
Published in
Frontiers in Genetics
Background Renal cell carcinoma (RCC) is the most prevalent type of malignant kidney tumor in adults, with clear cell renal cell carcinoma (ccRCC) comprising about 75% of all cases. The SETD2 gene, which is involved in the modification of histone proteins, is often found to have alterations in ccRCC. Yet, our understanding of how these SETD2 mutati...
Salzler, Harmony R Vandadi, Vasudha Matera, A Gregory
Published in
bioRxiv : the preprint server for biology
Dosage compensation in Drosophila involves upregulating male X-genes two-fold. This process is carried out by the MSL (male-specific lethal) complex, which binds high-affinity sites and spreads to surrounding genes. Current models of MSL spreading focus on interactions of MSL3 (male-specific lethal 3) with histone marks; in particular, Set2-depende...
gamallat, yaser lima, joema felipe seyedi, sima qiaowang, li rokne, jon george alhajj, reda ghosh, sunita bismar, tarek a.
SET-domain containing 2 (SETD2) is a histone methyltransferase and an epigenetic modifier with oncogenic functionality. In the current study, we investigated the potential prognostic role of SETD2 in prostate cancer. A cohort of 202 patients’ samples was assembled on tissue microarrays (TMAs) containing incidental, advanced, and castrate-resistant ...
Brockett, Jovan S Manalo, Tad Zein-Sabatto, Hala Lee, Jina Fang, Junnan Chu, Philip Feng, Harry Patil, Dattatraya Davidson, Priscilla Ogan, Kenneth
...
Published in
Genetics
Mutations in SETD2 are among the most prevalent drivers of renal cell carcinoma (RCC). We identified a novel single nucleotide polymorphism (SNP) in SETD2, E902Q, within a subset of RCC patients, which manifests as both an inherited or tumor-associated somatic mutation. To determine if the SNP is biologically functional, we used CRISPR-based genome...
Rosellini, Matteo Mollica, Veronica Marchetti, Andrea Coluccelli, Sara Giunchi, Francesca Tassinari, Elisa Ricci, Costantino Fiorentino, Michelangelo Tallini, Giovanni De Biase, Dario
...
Published in
Pathology, research and practice
Identifying biomarkers for metastatic renal cell carcinoma (mRCC) is an unmet need in actual immunotherapy era. Available data regarding chromosome 3p genes (i.e., VHL, PBRM1, SETD2) mutations as potential predictors for therapy response is conflicting. We describe the impact of these mutations on clinical outcomes in mRCC patients treated with imm...
Febres-Aldana, Christopher A. Fanaroff, Rachel Offin, Michael Zauderer, Marjorie G. Sauter, Jennifer L. Yang, Soo-Ryum Ladanyi, Marc
Diffuse pleural mesothelioma (DPM) is a highly aggressive malignant neoplasm arising from the mesothelial cells lining the pleural surfaces. While DPM is a well-recognized disease linked to asbestos exposure, recent advances have expanded our understanding of molecular pathogenesis and transformed our clinical practice. This comprehensive review ex...
Contreras Yametti, Gloria P Robbins, Gabriel Chowdhury, Ashfiyah Narang, Sonali Ostrow, Talia H Kilberg, Harrison Greenberg, Joshua Kramer, Lindsay Raetz, Elizabeth Tsirigos, Aristotelis
...
Published in
Leukemia & lymphoma
Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promotin...
Le Coadou, Louise
L'histone méthyltransférase SETD2 est responsable de la triméthylation de la lysine 36 sur l'histone H3. Cette marque épigénétique (H3K36me3) est notamment cruciale pour la régulation de la transcription, l'épissage et la réparation de l'ADN. De nombreuses études ont montré que SETD2 est un suppresseur de tumeur fréquemment muté dans le cancer. Cep...
Liu, Yang Li, Yunhao Xu, Haimin Zhou, Luting Yang, Xiaoqun Wang, Chaofu
Published in
International journal of surgical pathology
The last decade has seen great advances in genomic profiling and prognosis-associated factors of clear cell renal cell carcinoma (RCC), the most common entity in kidney cancer. Following VHL, PBRM1, SETD2, BAP1, and KDM5C have been validated as the most common co-occurring gene mutations in clear cell RCC by multicenter studies. However, the morpho...
Ma, Chunxiao Liu, Min Feng, Wenxin Rao, Hanyu Zhang, Wei Liu, Changwei Xu, Yue Wang, Ziyi Teng, Yan Yang, Xiao
...
Published in
Clinical and translational medicine
Colorectal cancer (CRC) is a complex, multistep disease that arises from the interplay genetic mutations and epigenetic alterations. The histone H3K36 trimethyltransferase SET domain-containing 2 (SETD2), as an epigenetic signalling molecule, has a 5% mutation rate in CRC. SETD2 expression is decreased in the development of human CRC and mice treat...
